The import of pharmaceutical products to Singapore has experienced notable fluctuations over the past decade. Between 2013 and 2019, the compound annual growth rate (CAGR) saw variations, with significant increases in 2018 (17.62%) and 2020 (8.78%). The value reached $3.3147 billion in 2023, marking an increase of 3.06% from 2022, though this was after a decline seen from 2021 to 2022.
Key trends over the forecasted period (2024-2028) indicate a steady growth with a forecasted CAGR of 2.01%. The expected total growth rate over the next five years is projected to be 10.44%, maintaining a positive trajectory following a decade of varied growth rates.
Future trends to watch for:
- Aging population and increasing healthcare needs.
- Potential impacts of global supply chain changes.
- Advancements in pharmaceutical technologies and innovation.
- Regulatory and policy shifts affecting healthcare imports.
